Gut Microbiome–Driven Colorectal Cancer via Immune, Metabolic, Neural, and Endocrine Axes Reprogramming

UDC.coleccionInvestigación
UDC.departamentoBioloxía
UDC.grupoInvRegulación da Expresión Xénica e Aplicacións (EXPRELA)
UDC.institutoCentroCICA - Centro Interdisciplinar de Química e Bioloxía
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruña
UDC.issue21
UDC.journalTitlenpj Biofilms and Microbiomes
UDC.volume12
dc.contributor.authorBautista, Jhommara
dc.contributor.authorLamas, Mónica
dc.contributor.authorHidalgo, Camila
dc.contributor.authorGuerra Guerrero, Antonio
dc.contributor.authorBetancourt-Velarde, Anapaula
dc.contributor.authorLópez-Cortés, Andrés
dc.date.accessioned2026-11-13T12:42:33Z
dc.date.available2026-11-13T12:42:33Z
dc.date.issued2026-01-27
dc.description.abstract[Abstract] Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide and is increasingly recognized as the outcome of complex host–microbe interactions. Beyond established genetic and environmental drivers, the gut microbiome has emerged as a causal and mechanistic contributor to CRC initiation, progression, and therapy response. This review synthesizes current molecular, ecological, and translational evidence to explain how gut microbial communities reprogram immune, metabolic, neural, and endocrine networks within the tumor microenvironment. CRC-associated dysbiosis is characterized by enrichment of pathobionts such as Fusobacterium nucleatum, pks⁺ Escherichia coli, and enterotoxigenic Bacteroides fragilis, and by loss of protective, short-chain-fattyacid-producing commensals. These microbes promote carcinogenesis through genotoxin-induced DNA damage, epithelial barrier disruption, metabolic rewiring, and chronic inflammation that collectively sustain immune suppression and tumor growth. Defined mutational signatures from bacterial metabolites, including colibactin, cytolethal distending toxin, and indolimines, now directly link microbial exposures to human cancer genomes. By integrating these findings, this review conceptualizes CRC as a biofilm-structured, microbiome-driven ecosystem disease, where polymicrobial consortia coordinate barrier breakdown, immune evasion, and metabolic cooperation. Finally, we highlight emerging microbiota-targeted strategies, including dietary modulation, pre- and probiotics, postbiotics, bacteriophage therapy, engineered live biotherapeutics, and fecal microbiota transplantation, that translate these insights into precision prevention and therapy. Through this integrative framework, the review aims to reposition the microbiome from a correlative feature to a tractable determinant of CRC pathogenesis and treatment response.
dc.description.sponsorshipThis work was supported by Universidad de Las Américas (UDLA) from Quito, Ecuador.
dc.identifier.citationBautista, J., Lamas-Maceiras, M., Hidalgo-Tinoco, C. et al. Gut microbiome–driven colorectal cancer via immune, metabolic, neural, and endocrine axes reprogramming. npj Biofilms Microbiomes 12, 21 (2026). https://doi.org/10.1038/s41522-025-00883-8
dc.identifier.doi10.1038/s41522-025-00883-8
dc.identifier.issn2055-5008
dc.identifier.urihttps://hdl.handle.net/2183/50242
dc.language.isoeng
dc.publisherNature
dc.relation.urihttps://doi.org/10.1038/s41522-025-00883-8
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleGut Microbiome–Driven Colorectal Cancer via Immune, Metabolic, Neural, and Endocrine Axes Reprogramming
dc.typereview
dspace.entity.typePublication
relation.isAuthorOfPublication46aaa211-8c28-4f28-90a9-7027c21f3fe1
relation.isAuthorOfPublication.latestForDiscovery46aaa211-8c28-4f28-90a9-7027c21f3fe1

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Lamas_Monica_2026_ Gut_Microbiome–Driven_Colorectal_Cance_via_Immune.pdf
Size:
2.07 MB
Format:
Adobe Portable Document Format